로딩 중…
지수 로딩 중…
한국비엔씨
256840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,585+6.82%
2026-08-04
Financials
Valuation Metrics
한국비엔씨's Market Cap is ₩1768B. At end of 2025 it was ₩3064B. Ranked #893 of 2,436 in KR market (top 37%), #419 of 1,649 on KOSDAQ (top 25%), #98 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.80B KRW | KR#893/2,436 Sec#98/234 |
| Revenue | 91.21B KRW | KR#1,446/2,436 Sec#90/234 |
| Net Income | -4.37B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 276.62B KRW | KR#1,057/2,436 Sec#72/234 |
| Net Assets | 233.41B KRW | KR#843/2,436 Sec#57/234 |
| Employees | 266 | KR#878/2,436 Sec#73/234 |
| Value | ||
| P/B | 0.76x | KR#1,224/2,436 Sec#69/234 |
| P/S | 1.94x | KR#1,805/2,436 Sec#103/234 |
| FCF Yield | 0.08% | KR#1,210/2,436 Sec#92/234 |
| Profitability | ||
| ROE | -1.87% | KR#1,608/2,436 Sec#113/234 |
| ROA | -1.58% | KR#1,661/2,436 Sec#118/234 |
| Op. Margin | -4.00% | KR#1,830/2,436 Sec#124/234 |
| Revenue Growth | -18.45% | KR#2,041/2,436 Sec#186/234 |
| Earnings Growth | -126.06% | KR#1,420/2,436 Sec#91/234 |
| Financial Health | ||
| Debt Ratio | 18.51% | KR#44/2,436 Sec#8/234 |
| Total Debt | 25.00B KRW | KR#1,278/2,436 Sec#104/234 |
| FCF | 145.0M KRW | KR#1,213/2,436 Sec#92/234 |
| Cash | 94.81B KRW | KR#481/2,436 Sec#25/234 |
| Current Ratio | 5.10x | KR#285/2,436 Sec#53/234 |
| Dividend | ||
| Div. Yield | 2.89% | KR#699/2,436 Sec#36/234 |
| Performance | ||
| 1Y Return | -48.40% | KR#2,045/2,436 Sec#190/234 |
| 1M Return | -1.15% | KR#1,012/2,436 Sec#96/234 |
| From 52W High | -58.17% | KR#1,619/2,436 Sec#137/234 |
| 1Y MDD | -64.13% | KR#1,651/2,436 Sec#136/234 |
| Trading | ||
| Volume | 272,215 shares | KR#436/2,436 Sec#42/234 |
| Foreign Own. | 6.06% | KR#703/2,436 Sec#68/234 |
| Per Share | ||
| EPS | -48 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,332 KRW | KR#1,740/2,436 Sec#133/234 |
Company Info
동사는 2007년 설립되어 2019년 코스닥시장에 상장한 생체재료 기반 의료기기 전문기업임. 히알루론산과 콜라겐을 가공하여 더말필러, 보툴리눔톡신 등 미용성형용 의료기기, 창상피복재 등 수술시술용 의료기기를 개발 및 생산하며, 생명공학 관련 연구용 시약 및 키트의 바이오유통사업을 영위하고 있음. 세종시에 의약품 GMP 생산시설을 구축하여 보툴리눔톡신 국내품목허가를 획득하는 등 의료기기에서 바이오의약품으로 사업영역을 확장하고 있음. 한국비엔씨는 2016년에 설립되었으며 대구광역시 달서구에 본사를 두고 있습니다.